www.biocat.cat

BIOREGION OF CATALONIA

CATALONIA

WITH A LONG INDUSTRIAL TRADITION, CATALONIA HASA DENSE AND INNOVATIVE INDUSTRIAL COMMUNITY• 6% OF SPANISH TERRITORY• 16% OF POPULATION (7.5M INHABITANTS)• 20% OF GDP• 47% OF PHARMACEUTICAL INDUSTRY• 19.4% OF BIOTECHNOLOGICAL INDUSTRY• 23% OF INVESTMENT IN R&D

BARCELONA LEADS THE TOP 10 MAJOR EUROPEAN CITIES OF THE FUTURE 2016/2017

CATALONIA IS THE FOURTH REGION IN ALL OF EUROPE IN TERMS OF FOREIGN INVESTMENT ATTRACTION IN 2015Sources: Farmaindustria, Asebio, Financial Times' FDI Markets

BARCELONA

THE BIOREGION OF CATALONIAA COMPETITIVE AND INNOVATIVE LIFE SCIENCES AND HEALTHCARE ECOSYSTEMCatalonia is the most dynamic bioregion in Spain and one of the most active in Europe. With a population of more than 7.5 millions and territory comparable to Finland, Belgium, the Netherlands and Israel, the BioRegion of Catalonia brings together 734 companies and 89 research organizations, including 41 research centers, 15 university hospitals, 11 universities offering life sciences studies, 13 sciences and technology parks with activity in the life sciences and large research facilities like the Alba-Cells Synchroton and the Barcelona Supercomputing Center (BSC). Barcelona and its metropolitan area are home to 90% of the Catalan life sciences industry.

BIOCAT BUILDING NOW WHAT THE ECOSYSTEM NEEDS NEXTBiocat has been a strategic player and catalyst in building the Catalan healthcare and life sciences ecosystem.Created in 2006 by the Government of Catalonia and the Barcelona City Council, Biocat is a foundation that boosts public and private stakeholders in the BioRegion (including companies, groups and research organizations, university hospitals, science parks and other support bodies to innovation) in order to transform knowledge and technology into economic growth and social impact.

SINCE 2000, CATALONIA HAS DEVELOPED ITS OWN SUCCESSFUL RESEARCH ECOSYSTEM

2000

KEY SUCCESS FACTORS:• Sustained funding from Catalan Government • Research centers autonomy• Independent evaluation• Funding based on results• High performance in attracting EU funds• Open talent recruitment program (ICREA)

2016

Source: Biocat Directory (September 2015)

734

89COMPANIES

RESEARCHORGANIZATIONS

THE BIOREGION OF CATALONIA, A GROWING AND INNOVATIVE ECOSYSTEM

BIOTECH

PHARMA

MEDTECH (R&D)

SUPPLIER & ENGINEERING

PROFESSIONAL SERVICES

INVESTMENT ENTITIES

RESEARCH CENTERS

UNIVERSITY HOSPITALS

UNIVERSITIES

SCIENCE & TECHNOLOGY PARKS

TECHNOLOGY CENTERS

LARGE FACILITIES

221

4694

208

13926

41

15

11

137

2

(OUT OF 101 HOSPITALS)

(OFFERING LIFE SCIENCES STUDIES)

EMPLOYMENT AND RESOURCES

Sources: Biocat Directory (Dec. 2014), Catalan Union of Hospitals, Government of Catalonia and SAVI

COMPANIES RESEARCH CENTERS HOSPITALS

+5,000RESEARCHERS

8,700WORKERS

+89,000 WORKERS

5,499RESEARCHERS (EMPLOYED BY THE UNIVERSITY HOSPITALS

AND RESEARCH INSTITUTES)

(195 ESTABLISHMENTS)42,133

BIOTECH14,278

PHARMA9,989

OTHERS6,622

MEDTECH 11,244

WORKERS

COMPANIES HAD REVENUES OF 14,369 M€ AND CONTRIBUTED

WITH 7% TO THE GDPIN CATALONIA

IN 10 YEARS, WORKERS IN R&D HAVE INCREASED 50% AND RESEARCHERS 60%

R&D SPENDING IN CATALONIA REPRESENTS 1.5% OF GDP (2,938 M€)23% OF SPANISH INVESTMENT IN R&D

Source: Farmaindustria, INE (2014)

355 M€PHARMA

INDUSTRY

147 M€ BIOTECH

COMPANIES

666 M€ UNIVERSITIES

AN INTERNATIONAL COMPETITIVE R&D SYSTEM

Source: Government of Catalonia TOTAL AMOUNT OF UNIVERSITIES WORLDWIDE (APROX.): 30,000

ICIQ1ST WORLD INSTITUTION

IN CHEMISTRYMax Plank Institute (2014)

ICFO 1ST WORLD INSTITUTION

IN PHYSICS Max Plank Institute (2013)

11 UNIVERSITY AMONG

THE 49 TOPUNIVERSITIES

IN THE WORLD INSCIENTIFIC

PRODUCTION(UB)

URAP (2015-2016)

33 UNIVERSITIES

AMONGTHE 50 BEST

UNDER50 YEARS

(URV, UAB, UPF)

QS TOP-50 UNIVERSITIESUNDER 50 YEARS (2014)

19TH BEST STUDENTCITY OF

THE WORLD

BARCELONA

QS BEST STUDENTS CITIES 2015

2

2 UNIVERSITIES AMONG THE 200

BEST INTHE WORLD

(UB, UAB)

TIMES HIGHER EDUCATION (2015)

CRG9TH IN THE TOP 100 BEST BIOMEDICAL CENTERS

IN THE WORLDScimago Report (SIR 2013)

33.4

32.8

22.2

18.2

6.7

ARTICLES PER MILLION INHABITANTS(2008-2012)

Source: Government of Catalonia

WITHOUT CATALONIA

In terms of publications inScience & Nature, Catalonia

doubles in numbers countries such as Germany or France

RESEARCHERS WORKING IN CATALONIA PUBLISH AT LEVELS COMPARABLE TO THOSE OF THE LEADING EUROPEAN COUNTRIES

CATALONIA PRODUCES 3.15% OF ALL SCIENTIFIC PRODUCTION IN EUROPE AND 0.99% IN THE WORLD, AND 29% OF PUBLICATIONS IN SPAIN

Source: Scopus / Observatori de la Recerca (OR-IEC), Institut d’Estudis Catalans

THE NUMBER OF LIFE SCIENCESAND HEALTHCARE PUBLICATIONS ROSE 168% FROM 2000 TO 2015

Publications(life sciences)

% EU28 % world

20092004 20112006 20102005 20082003200220012000 20122007 2013 2014 2015

4%

5%

2%

3%

1%

0%

10K

12,5K

5K

7,5K

2,5K

0K

THE MORE CHALLENGING AND COMPETITIVE A CALL IS,THE BETTER CATALONIA PERFORMSEUROPEAN RESEARCH COUNCIL (ERC) CALLS ARE THE MOST RESTRICTIVE AMONG EU'S CALLS (LESS THAN 10% APPLICATIONS ARE AWARDED)

With 27 grants per million inhabitants, Catalonia ranks 4th

in the European Research Area and 2nd in the European Union

COUNTRY ERC GRANTS PER MILLION INHABITANTS (2007-2015)

51.946.3

34.527.3

23

21.118.3

17.9

16.217.3

14.811.911.9

11.010.7

10

8.39.3

5.85.6

5.0

3.74.7

3.13.0

22.4

H2020 FUNDS ATTRACTED TO CATALONIA SHOW THE COMPETITIVINESS AND EXCELLENCE OF INSTITUTIONS, COMPANIES AND RESEARCHERS

Source: AGAUR from Eurostat 2013 / CORDA 2015

CATALONIA HAS ATTRACTED 73% MORE FUNDS FROM THE H2020 THAN THE TWO FIRST YEARS OF THE FP7. The two first years of H2020, Catalonia received 226.8 M€. Compared to other countries from the European Research Area (ERA) and with similar population, Catalonia overcomes Israel and Switzerland in absolute figures

DENMARK

FINLAND

AUSTRIA

CATALONIA

ISRAEL

SWITZERLAND 14

20

31

37

41

30

Country Inhabitants (in M) M€

Funding received per population

(ratio)

DENMARKFINLANDAUSTRIACATALONIAISRAELSWITZERLAND

5.6035.4278.4897.5477.7978.037

230.33119.79265.73226.77154.91108.67

413731302014

A WIDE RANGE OF CUTTING-EDGE FACILITIES THAT SUPPORT THE R&D SYSTEM

CENTER FOR GENOMIC REGULATION (CRG)

BARCELONA SUPERCOMPUTING CENTER (BSC - CNS)

ALBA SYNCHROTRON-CELLS

BARCELONA BIOMEDICAL RESEARCH PARK (PRBB)

BARCELONA SCIENCE PARK (PCB)

AND BRING TOGETHERTHE PLAYERS OF THEVALUE CHAIN:UNIVERSITIES, RESEARCHCENTERS AND COMPANIES

MORE THAN 100 PLATFORMS 2 LARGE INFRASTRUCTURES OF RESEARCH

13 SCIENCE AND TECHNOLOGY PARKS

5,499RESEARCHERS

8,716EMPLOYEES

780RESEARCH GROUPSWORKING ON LIFE

SCIENCES

41 RESEARCH CENTERS

NEW INITIATIVES AND GROUPINGS 2015: Barcelona Institute of Science and TechnologyBIST

+ +

CATALONIA,THE FOREMOST REGIONIN SPAIN IN TERMS OF

CLINICAL RESEARCH(2004-2011)

11 OUT OF THE

TOP20 BEST HOSPITALS IN SPAIN ARE LOCATED

IN CATALONIA

1ST

POSITION PERFORMING CLINICAL

TRIALS (27.3 %)

15 UNIVERSITY HOSPITALS AND9 HOSPITAL RESEARCH INSTITUTES

Source: Farmaindustria, IASIST (2015)

A HOT SPOT FOR BUSINESS AND INNOVATION7% GDP OF CATALONIA

Biotechnology- Therapeutics and diagnostics

Supplier & Engineering Investment entities

Professional Services and Consulting

Biotechnology - Other Pharma

Biotechnology - R&D services Medical Technology

734companies

6% 30%

13%

11%

28%

19%

13%

6%4%

Biotech

Pharma

Medtech

Others

TURNOVER (M€) COMPANIES

9,9892,910

14,2786,852

11,2443,092

6,6221,514

14,369M€ 42,133(4,000 in R&D)

WORKERS

Source: Biocat Directory

WHEN COMPARING NUMBER OF COMPANIES IN EUROPE, CATALONIA IS WITHIN THE TOP 5 LEADING COUNTRIESDESPITE BEING AMONG THE 5 SMALLEST COUNTRIES, CATALONIA STANDS IN THE TOP 5 IN NUMBER OF COMPANIES IN ALL SECTORSPer million inhabitants:- Biotech companies: Catalonia stands in 4th position after Sweden, Switzerland and Israel- Medtech companies: Catalonia stands in 4th position after Israel, Sweden and Switzerland- Pharma companies: Catalonia stands in 2nd

position, after Belgium

Million Inhabitants

2016

Biotech companies

Biotech Therapeutics companies

Medtech R&D

companies

Pharma companiesPer capita Per capita Per capita Per capita

AUSTRIA 8.713 94 10.79 40 4.59 52 5.97 15 1.72

BELGIUM 11.338 265 23.37 50 4.41 135 11.91 74 6.53

DENMARK 5.721 137 23.95 58 10.14 71 12.41 10 1.75

FINLAND 5.499 82 14.91 14 2.55 37 6.73 10 1.82

FRANCE 64.574 720 11.15 138 2.14 160 2.48 94 1.46

GERMANY 81.762 1,042 12.74 159 1.94 572 7.00 103 1.26

IRELAND 4.668 65 13.92 18 3.86 39 8.35 11 2.36

ISRAEL 8.377 334 39.87 154 18.38 545 65.06 36 4.30

ITALY 60.617 518 8.55 59 0.97 104 1.72 87 1.44

NETHERLANDS 17.008 409 24.05 86 5.06 117 6.88 40 2.35

NORWAY 5.240 120 22.90 27 5.15 32 6.11 8 1.53

SWEDEN 9.824 408 41.53 115 11.71 301 30.64 41 4.17

SWITZERLAND 8.362 346 41.38 104 12.44 230 27.51 47 5.62

UNITED KINGDOM 65.593 979 14.93 246 3.75 275 4.19 110 1.68

CATALONIA 7.516 221 29.40 45 5.99 94 12.51 46 6.12

Source: Site Selection for Life Sciences Companies in Europe 2015. KPMG & Venture Valuation

A CLUSTER IN EXPANSIONBETWEEN 2013-2015, ON AVERAGE, 3 NEW COMPANIES WERE FOUNDED PER MONTH (THAT IS 1 NEW VENTURE BORN IN HEALTHCARE EVERY 10 DAYS)

Source: Biotechegate. Biocat Directory, March 2016. The rest of the slides are based on company figures published at Biocat Report 2015 (September 2015)

+100 NEW ESTABLISHED COMPANIES FROM 2013 TO 2015

94 SPIN-OFF EMERGED FROM UNIVERSITIES,RESEARCH INSTITUTESAND HOSPITALS (ACTIVE AT 2015) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

825

623

828

324

225

338 3

35

141

40

37

31

3

New companies Inactive

COMPANIES ATTRACTED MORE THAN 100 M€ IN INVESTMENTS (2013-2015)

Source: BiotechGate. Biocat Directory: Last updated March 2016.

Capital raised by companies legally established at the BioRegion (thus it does not include Palobiopharma nor Sanifit)MAB: Spanish sub-market for smaller, growing companies

Direct investmentMAB

Projected December 2015 and March 2016

2009 201120102008

13.5610.60 10.50

10.61 11.00

29.50

10.6818

2.4455.16

3.62

3.44.31 4.3

2012 2013 2014 2015 2016

60

50

40

30

20

10

0

(in

M€)

87% OF BIOREGION COMPANIES ARE SMEsBIG COMPANIES ARE MAINLY MULTINATIONAL PHARMAs

Source: Biocat Directory / SABI

Over the past two years (2013-2015) the number of medium-sized companies has doubled and accounts for 22% of all companies, which is a sign of progressive consolidation in the sector

Medium-sized <250 ≤€50M ≤€43M

Small <50 ≤€10M ≤€10M

Micro <10 ≤€2M ≤€2M

Companycategory

Employees Balancesheet total

Turnover

Large companiesMedium-sized companies

Small companiesMicro-companies

40%

26%

22%

12%

734companies

58% OF COMPANIES ARE TRADING THEIR PRODUCTS IN INTERNATIONAL MARKETS

Source: Biocat Internationalization Survey 2015

THE MAIN MARKET FOR CATALAN COMPANIES IS SPAIN

Europe is the main destination for exports and international sales (mainly Germany, Italy and France) along with the United States

Collaborations Future entrySales

United States

Germany

United Kingdom

Spain

Italy

France

Mexico

Brazil

China

Japan

Colombia

Canada

India

Netherlands

Australia

South Korea

Israel

Argentina

Belgium

Sweden

19% 19% 26%

21% 16% 13%

13% 11% 14%

23% 11% 1%

18% 10% 7%

16% 7% 12%

14% 2% 2%

7% 1% 9%

7% 2% 6%

5% 3% 4%

4% 1% 6%

2% 6% 3%

2% 4% 3%

3% 3% 2%

3% 1% 4%

2% 2% 3%

2% 1% 4%

2% 2% 2%

1% 2% 2%

1% 2% 1%

BIOTECH: ACTIVITY OF COMPANIES

Source: Biocat Directory (December 2014)

THERAPIES & DIAGNOSTICS

R&D SERVICES

BIOTECH-OTHER*

ACTIVITIES COMPANIES

45

84

92

*Each company may be included into more than one category

2013 2015

0 10%5% 20%15% 30%25% 40%35% 45%

Environmental

AgBio

Industrial Biotechnology

Nutraceuticals

Cosmetics

Food

Veterinary

Others

BIOTECH & PHARMA: ACTIVITY OF COMPANIES(WORKING IN THERAPEUTIC AREAS)

Source: Biocat Directory

Each company can be included in more than one category

Generics 20%

18%

15%

10%

10%

9%

9%

8%

5,5%

3%

2%

2%

1%

1%

59%

Small molecules

Anti-infectives

Molecular diagnostics

Vaccines

Drug delivery

Antibodies

Peptides

Proteins

Gene therapy

Biosimilars

Cell therapy

Nucleic acid drugs

Stem cells

Others

0 20% 40% 60%

BIOTECH & PHARMA: ACTIVITY OF COMPANIES(OFFERING SERVICES R&D)

Source: Biocat Directory

CRO

Analytical services

Diagnostic services

CMO

Diagnostic instrumentation

Synthesis services

Genomics

Screening

Bioinformatics

Proteomics

Drug delivery

Cell culture

Biochips

Fill & finish

0 10% 20% 30% 40%

36%

25.5%

15%

14%

13%

12%

11%

7.5%

4%

3%

3%

3%

3%

0.5%

Others 29.5%

Each company can be included in more than one category

BIOTECH & PHARMA: MAIN THERAPEUTIC AREAS

Source: Biocat Directory

Neoplasms / cancer / oncology

Skin and subcutaneous tissue

Infectious and parasitic diseases

Diseases of the nervous system

Respiratory

Musculoskeletal system and connective tissue

Genitourinary system

Cardiovascular

Endocrine, nutritional and metabolic diseases

Diseases of the blood and blood-forming organs; immune disorders

Digestive system

Mental and behavioural disorders

Diseases of the eye

Pregnancy, childbirth and the puerperium

Diseases of the ear

Injury, poisoning and certain other consequences of external causes

External causes of morbidity and mortality

Congenital malformations, deformations and chromosomal abnormalities

Conditions originating in the perinatal period

0 10% 20% 30% 40%

37%

31%

27.5%

27.5%

22%

20%

20%

20%

19%

16.5%

15%

12%

10%

5%

4%

3%

1.5%

1.5%

1.5%

1.5%

Each company can be included in more than one category

MEDTECH: ACTIVITY OF COMPANIES (WORKING IN R&D, PRODUCTION AND MARKETING OF SYSTEMS AND DEVICES FOR MEDICAL APPLICATIONS IN HUMANS AND ANIMALS)

Source: Biocat Directory

Reusable instruments

Dental devices

Electro mechanical medical devices

Single use devices

Non-active implantable devices

Anesthetic and respiratory devices

Imaging

Diagnostic devices

Ophthalmic and optical devices

Technical aids for disabled persons

Diagnostic and therapeutic radiation devices

Biomaterials

Wound Care

Delivery devices

Hospital Hardware

Coatings

Regenerative Medicine

Others

0 10% 20% 30% 40%

COMPANIES WORKING IN MEDTECH:

R&D, PRODUCTION& MKT OFMEDICAL DEVICES

SOFTWARE, ELECTRONICS, INSTRUMENTATION OR DISTRIBUTION

94

106

200COMPANIES

19.5%

18%

17.5%

15%

12.5%

9.5%

9%

9%

9%

5%

4.5%

4.5%

2%

2%

2%

1%

1%

37%

Each company can be included in more than one category

WORLDWIDE INDUSTRY LEADERS CHOOSE THE BIOREGION AS THE BEST PLACE TO INVEST AND DO BUSINESSBIG MULTINATIONALS AND LOCAL BIG PLAYERS ESTABLISHED IN THE BIOREGIONBIOTECH & PHARMA MEDTECH

ACCELERATING PROGRAMS IN HEALTHCARE AT THE BIOREGIONEMPOWERING START-UPS AND ENTREPRENEURS TO SCALE UP THEIR BUSINESSES

PROGRAM / ACCELERATORCAIXAIMPULSE

d·HEALTH BARCELONA

HEALTH-U

SPIRE BIOVENTURES

WHAT IF! BARCELONA

GRANTS 4 APP

TECH4HEALTH

BSTARTUP

INCUBIO

INSPIRIT LABS

KAUTIC40

EMPENTA

IQSTECHFACTORY

STARTUPBOOTCAMP

STARTUP NEXT1

WAYRA

LIFE SCIENCES

LIFE SCIENCES

LIFE SCIENCES

LIFE SCIENCES

LIFE SCIENCES

DIGITAL HEALTH

DIGITAL HEALTH

IT

IT

IT

IT

ANY SECTOR

ANY SECTOR

ANY SECTOR

ANY SECTOR

ANY SECTOR

6 MONTHS

9 MONTHS

6 MONTHS

N/A

8 MONTHS

6 MONTHS

10 MONTHS

6 MONTHS

12 MONTHS

N/A

9 MONTHS

5 MONTHS

N/A

3 MONTHS

6 WEEKS

12 MONTHS

15 PROJECTS

3-4 PROJECTS

6 START-UPS

N/A

10 PROJECTS

4 START-UPS

15 START-UPS

10 START-UPS

7 START-UPS

1-2 PROJECTS

10 PROJECTS

15 PROJECTS

N/A

10 START-UPS

10 PROJECTS

10 PROJECTS

LA CAIXA

BIOCAT

SANOFI

SPIRE

INNOVATION FORUM

BAYER

HOSPITAL SANT JOAN DE DÉU, ESTEVE, CAIXA CAPITAL RISC, NAE, SHIP2B, DKV

BANC DE SABADELL

INCUBIO

INSPIRIT

ORBITAL 40

GENERALITAT DE CATALUNYA, ESADECREÁPOLIS

IQS

STARTUPBOOTCAMP

TECHSTARS

TELEFÒNICA

INDUSTRY DURATION COHORTSPROMOTERS

d·HEALTH BARCELONA

1 Last Startup Next Barcelona edition in April 2016

OUR LEADING TALENT

Valenti Fuster, cardiologistDirector of Mount Sinai Heart (New York). Editor-in-Chief of the Journal of the American College of Cardiology (JACC), past President of the American Heart Association

Josep Baselga, oncologistPhysician-in-Chief at Memorial Sloan Kettering Cancer Center (New York)

Josep M. Gatell, infectious diseasesHead of the Infectious Diseases and AIDS Units of the Hospital Clinic of Barcelona 

Joan Massagué, oncologistDirector of the Sloan-Kettering Institute (New York). Internationally recognized leader in the study of cancer metastasis and cell behavior

Manel Esteller, oncologistDirector of the Cancer Epigenetics and Biology Program of the Bellvitge Institute for Biomedical Research (IDIBELL, Barcelona)

SUCCESS STORIES

CATALAN FIRM ORYZON

TO RECEIVE 21 M$ FROM

ROCHE TO DEVELOP

EPIGENETICS DRUGS

SUCCESS STORIESTHE COMPANY, SPECIALIZED IN DRUG DEVELOPMENT FOR RARE OR MINORITY DISEASES, GETS MOST SIGNIFICANT FUNDING IN BIOTECH SECTOR IN CATALONIA

MINORYX THERAPEUTICSCOMPLETES SERIES A FUNDINGOF 19.4 M€ (21.7 M$)

SUCCESS STORIES

REIG JOFRE AND NATRACEUTICAL AGREE TO

MERGER, CREATING FIFTH LARGEST PUBLICLY

TRADED PHARMACEUTICAL COMPANY

SUCCESS STORIES

AELIX THERAPEUTICS FINISHES SERIES A THERAPEUTIC HIV

VACCINE FUNDS

SUCCESS STORIES

STAT-DIAGNOSTICA

SECURES 22.1 M$ IN

SERIES B FINANCING

STAT-DIAGNOSTICA ANNOUNCES 25 M€IN SERIES C FINANCING

SUCCESS STORIES

MEDTEP CLOSES A 2 M$ INVESTMENT

AND MOVES TO SAN FRANCISCO

SUCCESS STORIES

GALGO MEDICAL RAISES 1 M€ IN FUNDING

More information about the BioRegion of Catalonia at:Biocat Report 2015

http://informe.biocat.cat/en

Follow us:

More information about the BioRegion of Catalonia at:Biocat Report 2015

http://informe.biocat.cat/en

Silver sponsors: